8-K: Bellevue Life Sciences Acquisition Corp. Amends Business Combination Agreement with OSR Holdings, Adjusts Consideration and Board Composition

Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. have amended their business combination agreement, reducing the aggregate consideration and updating board designations.

Summary

• Bellevue Life Sciences Acquisition Corp. (BLAC) and OSR Holdings Co., Ltd. have amended their business combination agreement, initially established on November 16, 2023.
• The amended agreement removes the proposed acquisition of Landmark BioVentures AG by OSR Holdings.
• The aggregate consideration has been reduced from 25,033,961 to 24,461,214 shares of BLAC Common Stock.
• The aggregate consideration value has decreased from $250,339,610 to $244,612,136.
• Changes have been made to the designation of the post-closing Board of Directors of BLAC.
• Steven Reed resigned from the BLAC Board, and Phil Geon Lee was appointed as a new director.
• The agreement outlines the share exchange process, where BLAC will issue shares to participating OSR Holdings stockholders in exchange for their shares.
• The per share consideration is estimated at $129.62, subject to adjustment based on the fully diluted share amount of OSR Holdings.
• BLAC will hold at least 60% of OSR Holdings' fully diluted share amount after the share exchange.
• The agreement includes provisions for non-participating stockholders, who will have put and call rights for their shares.

Sentiment

Score: 5

Explanation: The document contains both positive and negative elements. The amendment of the agreement and reduction in consideration are negative, while the appointment of a new director and the inclusion of put and call rights for non-participating stockholders are positive. The overall sentiment is neutral.

Positives

• The amended agreement provides clarity on the terms of the business combination.
• The appointment of Phil Geon Lee brings extensive experience in legal and investment sectors to the BLAC Board.
• The agreement includes a mechanism for non-participating stockholders to exchange their shares in the future.

Negatives

• The reduction in aggregate consideration and value may be viewed negatively by some investors.
• The resignation of Steven Reed may cause some disruption in the board's operations.

Risks

• The business combination is subject to various closing conditions, including stockholder approval and regulatory clearances.
• The agreement includes forward-looking statements that are subject to risks and uncertainties.
• The inability to complete the business combination could negatively impact both companies.
• The COVID-19 pandemic and other global health disruptions could affect the ability to consummate the business combination.
• There is a risk that the consummation of the business combination disrupts the current plans and operations of OSR Holdings.
• The ability to recognize the anticipated benefits of the business combination may be affected by competition and the ability to raise additional capital.

Future Outlook

The document includes forward-looking statements regarding the satisfaction of closing conditions, the timing of the completion of the business combination, and the future performance of the company. These statements are subject to significant risks and uncertainties.

Management Comments

• The Board of Directors of BLAC formed a separate committee (the M&A Committee), consisting of independent directors, to review and consider these interests during the negotiation of the Business Combination Agreement, the A&R BCA, and in evaluating and unanimously approving, as members of the BLAC Board, the Business Combination Agreement and the A&R BCA.
• BLAC believes Mr. Lee is well qualified to serve as a director because of his extensive experience in both legal and investment sectors across various asset classes, demonstrating significant expertise in capital markets.

Industry Context

This announcement reflects a trend of special purpose acquisition companies (SPACs) seeking merger targets. The life sciences sector is a popular area for SPAC mergers, given the potential for high growth and innovation.

Comparison to Industry Standards

• The reduction in consideration is not uncommon in SPAC mergers, as market conditions and due diligence findings can lead to adjustments.
• The appointment of independent directors to the M&A committee is a standard practice to ensure fairness and transparency.
• The lock-up agreements are typical in these types of transactions to ensure stability post-merger.
• The per share consideration is subject to adjustment, which is a common practice to account for changes in the target company's capitalization.

Management Changes

Stakeholder Impact

• Shareholders of BLAC will vote on the proposed business combination.
• Shareholders of OSR Holdings will receive shares of BLAC Common Stock in exchange for their shares.
• Employees of both companies may be affected by the integration process.
• Customers and suppliers of both companies may experience changes as a result of the merger.

Next Steps

• BLAC will prepare and file a proxy statement/prospectus with the SEC.
• BLAC will mail the proxy statement to its stockholders.
• BLAC will hold a stockholder meeting to vote on the business combination.
• The parties will work to satisfy the closing conditions outlined in the agreement.

Key Dates

Keywords

business combination, merger, acquisition, share exchange, board of directors, stockholders, consideration, capital stock, warrants, proxy statement